F18.151 Inhalant abuse with inhalant-induced psychotic disorder with hallucinations

Name of the Condition

• Common Name: Inhalant Abuse with Inhalant-Induced Psychotic Disorder with Hallucinations
• Medical Term: Inhalant Abuse with Inhalant-Induced Psychotic Disorder with Hallucinations

Summary

Inhalant abuse with inhalant-induced psychotic disorder with hallucinations involves the intentional misuse of inhalants—substances that produce chemical vapors—to achieve psychoactive effects, accompanied by the development of psychotic symptoms, specifically hallucinations, directly attributable to inhalant use. This condition combines substance-related misuse with psychotic features, such as perceptual disturbances, and can lead to acute intoxication, dependence, and significant physical or psychological harm, impacting an individual's health and daily functioning.

Causes

Inhalant abuse is primarily driven by the repeated misuse of inhalants for their psychoactive effects. Inhalants are often everyday household or industrial products, such as glue, paint thinners, aerosols, or solvents. The misuse of these substances can lead to dependence and, in some cases, induce psychotic symptoms due to their neurotoxic effects on the central nervous system.

Risk Factors

• Adolescents and young adults are more likely to experiment with inhalants.
• Individuals with a history of substance abuse or mental health disorders.
• Accessibility to inhalant products.
• Lack of proper supervision or guidance.

Symptoms

• Intense cravings or compulsive inhalant use.
• Hallucinations (e.g., visual, auditory) directly linked to inhalant use.
• Coordination problems, dizziness, or lethargy.
• Unexplained behavioral changes such as aggression or mood swings.
• Cognitive impairment or memory issues.

Diagnosis

Clinical evaluation including a detailed history of inhalant use, physical examination, and assessment of symptoms. Laboratory tests may be used to rule out other conditions, and psychiatric evaluation helps confirm psychotic symptoms attributable to inhalant use.

Treatment Options

• Detoxification and withdrawal management under medical supervision.
• Pharmacotherapy to address psychotic symptoms or co-occurring disorders.
• Behavioral therapies (e.g., cognitive-behavioral therapy) to modify substance use patterns.
• Supportive care for physical and psychological complications.

Prognosis and Follow-Up

Prognosis depends on the severity of use, presence of co-occurring disorders, and adherence to treatment. Regular follow-up is essential to monitor for relapse, manage symptoms, and address long-term health effects. Early intervention improves outcomes.

Complications

• Persistent cognitive impairment.
• Worsening of psychotic symptoms.
• Physical harm from inhalant toxicity (e.g., organ damage).
• Increased risk of accidents or injuries due to impaired judgment.

Lifestyle & Prevention

• Avoid exposure to inhalant products when possible.
• Educate at-risk individuals about the dangers of inhalant misuse.
• Promote healthy coping mechanisms and stress management.
• Encourage open communication about substance use concerns.

When to Seek Professional Help

Seek immediate medical attention if experiencing severe hallucinations, confusion, or physical distress after inhalant use. Consult a healthcare provider for persistent symptoms, difficulty stopping use, or concerns about mental health.

Tips for Medical Coders

Document the presence of inhalant-induced hallucinations as a key feature of the psychotic disorder. Ensure clinical notes specify the direct attribution of hallucinations to inhalant use to support accurate coding. Verify that the code F18.151 is used when hallucinations are the predominant psychotic symptom.